ANI Pharmaceuticals | ANIP - Cost Of Sales


ANI Pharmaceuticals reported $122.88M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
ANI Pharmaceuticals USD 122.88M 6.86M Dec/2025
Assertio Holdings USD 8.89M 2.29M Jun/2024
Aurora Cannabis CAD 58.08M 11.99M Sep/2025
Canopy Growth CAD 44.78M 9.32M Sep/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Hikma Pharmaceutical USD 466.5M 428.5M Jun/2025
Knight Therapeutics CAD 47.25M 990K Sep/2024
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novartis USD 3.54B 216M Sep/2025
Omeros USD 33.16M 18.52M Jun/2024
Perrigo USD 747.4M 81.2M Dec/2025
Sun Pharmaceuticals INR 36.77B 348M Dec/2025
Teva Pharmaceutical Industries USD 2.06B 120M Dec/2025